It is made available under a CC-BY 4.0 International license .

Manuscript

*December* 18<sup>th</sup>, 2023

# **1** Persistent Hyposmia as Surrogate for α-Synuclein-Linked Brain Pathology

- 2
- 3 Brit Mollenhauer<sup>1,2,6,7\*</sup>, Juan Li<sup>3,4,6\*</sup>, Sebastian Schade<sup>2</sup>, Sandrina Weber<sup>1</sup>, Claudia Trenkwalder<sup>2</sup>,
- 4 Luis Concha-Marambio<sup>5</sup>, Julianna J. Tomlinson<sup>3,6,7</sup>, aSCENT-PD Investigators<sup>6,7</sup>, Michael G.
- 5 Schlossmacher<sup>3,6,7#</sup>
- 6
- <sup>7</sup> <sup>1</sup>Department of Neurology, University of Goettingen, Kassel
- 8 <sup>2</sup>Paracelsus-Elena-Klinik, Kassel, Germany
- 9 <sup>3</sup>Neuroscience Program, <sup>4</sup>Clinical Epidemiology Program, Ottawa Hospital Research Institute,
- 10 Ottawa, ON., Canada
- <sup>5</sup>Amprion, Inc.; San Diego, CA; USA
- <sup>6</sup>Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase,
- 13 MD. 20815
- 14 <sup>7</sup>aSCENT-PD Investigators include: Ben Arenkiel, Zhandong Liu, Brit Mollenhauer, Josef
- 15 Penninger, Maxime Rousseaux, Armen Saghatelyan, Natalina Salmaso, Michael G. Schlossmacher,
- 16 Christine Stadelmann-Nessler, Julianna J. Tomlinson, John M. Woulfe
- 17
- 18 \*These authors contributed equally
- 19 <sup>#</sup>The corresponding author
- 20
- 21 Michael G. Schlossmacher, MD, FRCPC
- 22 Ottawa Hospital Research Institute; Ottawa, Canada
- 23 mschlossmacher@toh.ca
- 24 Phone: +1 613-562-5462
- 25
- 26

It is made available under a CC-BY 4.0 International license .

Manuscript

*December* 18<sup>th</sup>, 2023

## 27 ABSTRACT

Impaired olfaction can be associated with neurodegenerative disorders. We examined odor 28 29 identification in newly diagnosed patients with parkinsonism and those at increased risk, measured 30 olfactory performances longitudinally, and juxtaposed results to cerebrospinal fluid (CSF) values. 31 Using Sniffin'-Sticks-Identification Tests (SST-ID), we examined 312 age-matched individuals at a German center, including: 126 with Parkinson disease (PD), 109 healthy controls, 25 with other 32 33 neurodegenerative disorders and 52 with a REM-sleep behavior disorder (RBD). As expected, PD patients had significantly lower SST-ID scores than controls. Scent identification by subjects with 34 35 other neurodegenerative diseases fell between those with PD and healthy individuals. Those with 36 isolated RBD, who subsequently converted to PD or dementia, had lower baseline scores than nonconverters. When monitoring olfaction in participants up to a decade, we saw small group 37 differences in progression rates for hyposmia. However, these variations were insignificant after 38 39 controlling for age, sex and length of intervals between testing. When analyzing participants' sense 40 of smell versus several CSF biomarkers linked to neurodegeneration, we found no correlation with 41 SST-ID scores. However, the means for normalized concentrations of  $\alpha$ -synuclein, total tau, 42 phosphorylated tau and amyloid- $\beta$  peptide<sub>42</sub> were reduced in PD. We also identified significant 43 age- and sex-linked differences in CSF values. Finally, we compared olfaction to the results of a 44 validated  $\alpha$ -synuclein 'Seed Amplification Assay' (SAA) using CSF. We found that hyposmia 45 strongly correlated with a positive CSF  $\alpha$ -synuclein SAA-test. We conclude that chronically impaired olfaction in older adults is strongly associated with a positive  $\alpha$ -synuclein SAA-test from 46 CSF but not with the concentrations of several, neuropathologically relevant CSF markers. We 47 48 posit that simple-to-administer, quantitative smell tests could serve as inexpensive screening tools 49 in future population studies for the identification of  $\alpha$ -synuclein-related brain disorders, including Parkinson's during its premotor phase. 50

51

It is made available under a CC-BY 4.0 International license .

Manuscript

December 18th, 2023

#### 53 MANUSCRIPT

54 Impaired olfaction can be associated with neurodegenerative disorders.<sup>1</sup> Its pathogenesis, 55 progression over time and any sex differences remain unknown. We examined odor identification

progression over time and any sex anterences remain anknown. We examined outer identification

- 56 in newly diagnosed patients with parkinsonism and those at increased risk, measured olfactory
- 57 performances longitudinally, and juxtaposed results to cerebrospinal fluid (CSF) values.
- 58 Using Sniffin'-Sticks-Identification Tests (SST-ID; scale, 0-16), we examined 312 age-matched
- 59 individuals at a single center<sup>2</sup>, including: 126 with Parkinson disease (PD), 109 healthy controls,
- 60 25 with other neurodegenerative disorders and 52 with a REM-sleep behavior disorder (RBD). In
- 61 16 RBD subjects, a neurodegenerative disorder<sup>3</sup> was subsequently diagnosed (**Suppl. TableS1**).

The participants' baseline SST-ID scores are shown in **Fig.1a**, with reduced olfaction defined as a score below the 10<sup>th</sup> percentile for each sex and age group.<sup>4</sup> As expected,<sup>1</sup> PD patients had lower SST-ID scores than controls (P<2e-16). Scent identification by subjects with other neurodegenerative diseases fell between those with PD (P=6.6e-05) and healthy individuals (P=0.018). Those with isolated RBD, who subsequently converted to PD or dementia, had lower baseline scores than non-converters (P=0.0021). There was no sex difference after controlling for age (**Fig.1a**).

When monitoring olfaction in participants up to a decade, we saw small group differences in progression rates for hyposmia (**Fig.1b**; **Suppl. Fig.S1**). However, these variations were insignificant after controlling for age, sex and length of intervals between testing.

72 When analyzing participants' sense of smell versus several CSF biomarkers<sup>2</sup> linked to 73 neurodegeneration, we found no correlation with SST-ID scores. However, the means for 74 normalized concentrations of α-synuclein, total tau, phosphorylated tau and amyloid-β peptide<sub>42</sub> 75 were reduced in PD. We also identified significant age- and sex-linked differences in CSF values 76 (**Suppl. Fig.S2**).

Finally, we compared olfaction to the results of a validated  $\alpha$ -synuclein 'Seed Amplification Assay' (SAA) using CSF. Positivity in this binary test has been shown to reflect  $\alpha$ -synuclein-linked brain

It is made available under a CC-BY 4.0 International license .

Manuscript

*December* 18<sup>th</sup>, 2023

- 79 pathology.<sup>5</sup> We found that hyposmia strongly correlated with a positive CSF  $\alpha$ -synuclein SAA-
- 80 test [R: 0.63; R<sup>2</sup>: 0.4 (P<2.2e-16); Fig.1c]. There was no age or sex difference in its outcome.

81 We conclude that chronically impaired olfaction in older adults is strongly associated with a 82 positive  $\alpha$ -synuclein SAA-test from CSF but not with the concentrations of several, 83 neuropathologically relevant CSF markers. Future studies will determine at what age hyposmia 84 and SAA-test positivity begin, and why. We posit that simple-to-administer, quantitative smell 85 tests could serve as inexpensive screening tools in future population studies for the identification 86 of  $\alpha$ -synuclein-related brain disorders, including Parkinson's during its premotor phase.

It is made available under a CC-BY 4.0 International license .

Manuscript

December 18th, 2023

#### 88 **REFERENCES**

- Haehner A, Hummel T, Reichmann H. (2011) Olfactory loss in Parkinson's disease.
   *Parkinsons Dis.* 2011:450939.
- Mollenhauer B, Trautmann E, Sixel-Döring F, Wicke T, Ebentheuer J, Schaumburg M,
   Lang E, Focke NK, Kumar KR, Lohmann K, Klein C, Schlossmacher MG, Kohnen R,
   Friede T, Trenkwalder C; DeNoPa Study Group. (2013) Nonmotor and diagnostic findings
   in subjects with de novo Parkinson disease of the DeNoPa cohort. *Neurology* 81(14): 1226 34
- 96 3. Postuma RB, Iranzo A, Hu M, Högl B, Boeve BF, Manni R, Oertel WH, Arnulf I, Ferini-97 Strambi L, Puligheddu M, Antelmi E, Cochen De Cock V, Arnaldi D, Mollenhauer B, 98 Videnovic A, Sonka K, Jung KY, Kunz D, Dauvilliers Y, Provini F, Lewis SJ, Buskova J, 99 Pavlova M, Heidbreder A, Montplaisir JY, Santamaria J, Barber TR, Stefani A, St Louis EK, Terzaghi M, Janzen A, Leu-Semenescu S, Plazzi G, Nobili F, Sixel-Doering F, Dusek 100 101 P, Bes F, Cortelli P, Ehgoetz Martens K, Gagnon JF, Gaig C, Zucconi M, Trenkwalder C, 102 Gan-Or Z, Lo C, Rolinski M, Mahlknecht P, Holzknecht E, Boeve AR, Teigen LN, Toscano 103 G, Mayer G, Morbelli S, Dawson B, Pelletier A. (2019) Risk and predictors of dementia 104 and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 105 142(3):744-759.
- Oleszkiewicz A, Schriever VA, Croy I, Hähner A, Hummel T. (2019) Updated Sniffin'
   Sticks normative data based on an extended sample of 9139 subjects. *Eur Arch Otorhinolaryngol.* 276(3):719-728.
- Arnold MR, Coughlin DG, Brumbach BH, Smirnov DS, Concha-Marambio L, Farris CM,
   Ma Y, Kim Y, Wilson EN, Kaye JA, Hiniker A, Woltjer RL, Galasko DR, Quinn JF. (2022)
   α-Synuclein Seed Amplification in CSF and Brain from Patients with Different Brain
   Distributions of Pathological α-Synuclein in the Context of Co-Pathology and Non-LBD
   Diagnoses. *Ann Neurol.* 92(4):650-662.

It is made available under a CC-BY 4.0 International license .

Manuscript

December 18<sup>th</sup>, 2023

#### 115 FIGURE

#### 116 Figure 1: Association of chronically reduced olfaction with α-synuclein-linked brain diseases

(A) Relationship between baseline SST-ID scores (y-axis) and disease group (columns), sex (rows),
and age at baseline enrolment (x-axis). Each square represents a participant. Classification of
olfaction (square colors) was defined by SST-ID scores at or below the 10<sup>th</sup> percentile for each sex
and age group, as published.<sup>4</sup> The "reduced olfaction" group includes both hyposmia and anosmia.

(B) Changes in SST-ID scores over time. The legend underneath the graph summarizes the color representation and corresponding number of participants in each group. Each square represents a study subject at a given time point, with overlap seen due to integer scores and number of months tracked. Each thin line tracks the changes of an individual participant, whereas thicker linear regression lines summarize the overall trend.

126 (C) A Cummings estimation plot was used to illustrate CSF  $\alpha$ -synuclein SAA-test results versus 127 SST-ID score distributions in each group at study enrolment. Each data point in the upper panel represents the score of each participant, with colors representing CSF  $\alpha$ -synuclein SAA-status as 128 129 either positive or negative. The vertical lines represent the conventional mean  $\pm$  standard deviation error bars. Lower panels show the mean group difference (i.e., effect size) and its 95% confidence 130 131 interval (CI) estimated by bias-corrected and accelerated bootstrapping, using healthy controls 132 (HC) as the reference group. SST-ID score and CSF  $\alpha$ -synuclein SAA-status distinguish PD patients from age- and sex-matched healthy controls with AUC values of 0.89 (95% CI 0.85-0.93) 133 134 and 0.95 (95% CI 0.92-0.98), respectively.

Abbreviations denote SST-ID as Sniffin'-Sticks-Identification test; DeNoPa, *De Novo* Parkinson
Study; RBD, isolated REM sleep behavior disorder; PD, Parkinson disease; HC, healthy control;
OND as other neurological diseases; CSF, cerebrospinal fluid; SAA, seed amplification assay.

It is made available under a CC-BY 4.0 International license .

Supplementary Appendix

December 18<sup>th</sup>, 2023

# 139 SUPPLEMENTARY APPENDIX

- 140 Supplement to: Mollenhauer B, Li J et al. Persistent Hyposmia as Surrogate of α-Synuclein-
- 141 Linked Brain Pathology
- 142 This appendix has been provided by the authors to give readers additional information about the
- 143 work.
- 144

It is made available under a CC-BY 4.0 International license .

Supplementary Appendix

December 18<sup>th</sup>, 2023

# 145 **TABLE OF CONTENTS**

146	SUPPLEMENTARY INFORMATION: METHODS	9
147	CODE AND DATA AVAILABILITY	11
148	TABLE S1	12
149	LEGENDS / SUPPLEMENTARY FIGURES	14
150	SUPPLEMENTARY REFERENCES	16
151 152	ACKNOWLEDGEMENTS	18

It is made available under a CC-BY 4.0 International license .

Supplementary Appendix

#### December 18<sup>th</sup>, 2023

## 154 SUPPLEMENTARY INFORMATION: METHODS

#### 155 Source of data and participants

156 We used de-identified data from the 'DeNoPa cohort', an ongoing, single-center study based at 157 the Paracelsus-Elena Klinik in Kassel, Germany. Data from this study were downloaded on May 158 16<sup>th</sup>, 2023. The cohort<sup>2</sup> represents an observational, longitudinal study of patients with a newly 159 established ("de novo") diagnosis of PD (UK Brain Bank Criteria<sup>2</sup>) that were naïve to L-DOPA 160 therapy at baseline, and of age- as well as sex-matched, neurologically healthy controls (HC). 161 Exclusion criteria included previously known or subsequently detected brain conditions, such as 162 normal pressure hydrocephalus, cerebrovascular disease, early cognitive impairment, features of 163 atypical parkinsonism, and medication-induced parkinsonism. HC subjects were recruited through 164 relatives and friends of enrolled PD subjects, other patients of the hospital-based clinic as well as 165 through newspaper advertisements in 2009. Control subjects had to be without any active, known 166 or previously treated condition of their central nervous system. Diagnostic accuracies for study participants were ensured by ongoing follow-up visits every two years (as of 2023, 10<sup>th</sup> year 167 168 follow-up visits are underway). Twenty-seven patients classified as PD at baseline were later re-169 grouped as patients with "other neurological diagnoses" (OND).

The 'DeNoPa RBD cohort' is a prospective study that follows patients with clinically diagnosed isolated RBD, using an inpatient polysomnogram and related questionnaires, with up to 8 years of follow-up. Both recruitment and follow-up visits are currently continuing. Conversion to PD and OND was confirmed based on the UK Brain Bank Criteria and other diagnostic criteria.<sup>3</sup> Of note, there is no overlap in participants between the two cohorts, and participants' olfactory function had no influence on their recruitment into either of the two cohorts.

The launch and ongoing analyses of these cohorts were approved by the Investigational Review
Board of Landesaerztekammer Hesse in Frankfurt, Germany (FF89/2008) and by the Regulatory
Ethics Board of The Ottawa Hospital in Ottawa, Canada (20180010-01H).

179

180 Procedures and statistical analyses

181 Sniffin' Sticks test (SST): SST comprises a supervised test for one's sense of smell using pen-like 182 odor dispensing devices and is done in the clinic.<sup>4</sup> This study focused on its Identification subtest

It is made available under a CC-BY 4.0 International license.

Supplementary Appendix

December 18<sup>th</sup>, 2023

183 (SST-ID) containing 16 items, in which subjects choose the odor in each stick from four options

184 (one correct, three distractors). The German language version of the SST-ID test was completed

185 by DeNoPa PD and HC participants at baseline and serially during follow-up visits, as well as by

186 RBD participants at baseline and during follow-up visits (see Figure 1.b for details).

187 An in vitro  $\alpha$ -synuclein-directed seed amplification assay (SAA): Methodological details of the

188 SAA test, which was performed at Amprion Inc., San Diego, CA. used in this study have been

189 described elsewhere.<sup>5</sup> The SAA data were available for a subset of DeNoPa (HC: 63; PD: 92; OND:

190 17) and RBD (n = 27) participants and downloaded on August 15<sup>th</sup>, 2023.

Biomarkers measured in cerebrospinal fluid (CSF): Methodological details of the CSF biomarkers quantification used in this study have been described elsewhere.<sup>6-8</sup> The CSF data at baseline were available for a subset of DeNoPa (HC: 61; PD: 98; OND: 19) participants and downloaded on May 10<sup>th</sup>, 2019. Five biomarkers, namely the concentrations of total α-synuclein, total tau, phosphorylated tau, amyloid-β peptide<sub>42</sub>, and total protein, were studied here (**Supplementary Figure S1 a-e**). The first four readouts were then further normalized using CSF total protein concentrations measurement in each person (**Supplementary Figure S1 f-i**).

198 Statistical analyses: Demographic and diagnostic characteristics of the study cohorts are 199 summarised using n (%) or median (the interquartile range (IQR)). The reported p-values represent 200 the significance from corresponding Chi-squared test, Welch Two Sample t-test, or ANOVA with 201 Bonferroni or Dunnett post-hoc test corrections, using the PD group as the reference group. 202 Coefficients reported in Supplementary Figures S1, S2 were calculated using multivariate linear 203 regression. Results with p-values smaller than 0.05 were considered significant. Statistical 204 analyses were performed using 'R' (version 4.2.0). Cummings estimation plots were generated using 'dabestr',<sup>9</sup> all other plots were generated using 'ggplot2'.<sup>10</sup> The package 'pROC'<sup>11</sup> was used 205 for generating ROC and AUC. 206

It is made available under a CC-BY 4.0 International license .

Supplementary Appendix

December 18<sup>th</sup>, 2023

# 208 CODE AND DATA AVAILABILITY

- 209 The code for data analyses and figures is publicly accessible in GitHub
- 210 (https://github.com/JuanLiOHRI/SAA). Data can be accessed via zenodo
- 211 (<u>https://zenodo.org/records/10222976</u>).

It is made available under a CC-BY 4.0 International license .

Supplementary Appendix

*December* 18<sup>th</sup>, 2023

# 213 **TABLE S1**

#### DeNoPa $RBD^2$ $OND^1$ PD Characteristic HC 126 109 25 Ν 52 67 (61.5) 15 (60) Sex: Male 82 (65.1) 35 (67.3) [p = 0.57][p = 0.63]Age at baseline in years 65 (10) 71 (12.0) All 66 (13.8) 68 (11.2) [p = 0.98][p = 0.01]67 (8) 70 (12) 66 (14.8) Male 68 (10.5) [p = 0.81][p = 0.20]64 (9.8) 74 (9.5) Female 66 (12.8) 68 (12) [p = 0.90][p = 0.03]Parkinsonism duration at 15 (25) 14.5 (14.75) n.a. n.a. baseline in months [p = 0.25]121 (4.0) 72 (69) Follow-up time in months 118 (48.5) 48.5 (57) [p = 0.05][p = 0.03]

#### 214 Demographic characteristics of adults enrolled in two single-centre cohorts from Germany

215

<sup>1</sup>Detailed diagnosis in the OND group: DLB = 3, ET = 6, MSA = 4, PSP = 5, RLS = 1, DD PD =

217 2, Vascular PD = 4.

<sup>2</sup> Detailed diagnoses in the converted cases in the RBD cohort: PD = 10, DLB = 5, DD PD = 1.

219 Values are n (%) or median (IQR). The reported p-values in square brackets represent the

significance from corresponding Pearson's Chi-squared test, Welch two sample t-test, or ANOVA

221 with Dunnett post-hoc test, using the PD group as the reference group.

222 DeNoPa = De Novo Parkinson Study. RBD = isolated REM sleep behavior disorder. IQR = the

223 interquartile range. PD = Parkinson disease. HC = healthy control. OND = other neurological

diseases. DLB = dementia with Lewy bodies. ET = essential tremor. MSA = multiple system

It is made available under a CC-BY 4.0 International license .

Supplementary Appendix

December 18<sup>th</sup>, 2023

- atrophy. PSP = progressive supranuclear palsy. RLS = restless leg syndrome. DD PD = uncertain
- 226 neurological diagnosis. n.a. = not available

It is made available under a CC-BY 4.0 International license .

Supplementary Appendix

*December* 18<sup>th</sup>, 2023

# 228 LEGENDS / SUPPLEMENTARY FIGURES

## 229 <u>Suppl. Figure S1:</u> Rate of changes of SST-ID scores over time.

- 230 The rate of change was calculated by dividing the score difference of two successive visits with
- 231 the time difference in months. The legend underneath the graph summarizes the color
- 232 representation and corresponding number of participants in each group. Each square represents a
- study subject at a given time point. Each thin line tracks the changes of an individual participant,
- 234 whereas thicker linear regression lines summarize the overall trend.
- 235 The table lists the coefficients and p-values of linear regression using "rate  $\sim$  month + group + age
- 236 + sex" as the formula.

It is made available under a CC-BY 4.0 International license.

Supplementary Appendix

December 18<sup>th</sup>, 2023

#### 238 <u>Suppl. Figure S2:</u> Relationship between select CSF biomarkers and disease group and sex.

- 239 (A-I) Cummings estimation plots were used to illustrate and compare select CSF biomarker
- 240 distributions, as indicated, in each study group. Each point represents a participant. Classification
- of olfaction (point colors) was defined as SST-ID scores below the 10<sup>th</sup> percentile in each sex and
- age group. The vertical lines represent the conventional mean  $\pm$  standard deviation error bars. The
- lower panels show the mean group difference (the effect size) and its 95% confidence interval (CI)
- estimated by bias-corrected and accelerated bootstrap, using HC in each sex as the reference group.
- 245 The table in each individual panel (A-I) lists the coefficients, p-values, and significance levels of
- linear regression using "biomarker  $\sim$  group + age + sex + olfaction" as the formula.
- 247 SST-ID = Sniffin' Sticks Identification test. DeNoPa = *De Novo* Parkinson Study. PD = Parkinson
- 248 disease. HC = healthy control. OND = other neurological diseases. CSF = cerebrospinal fluid.

249

It is made available under a CC-BY 4.0 International license .

Supplementary Appendix

December 18<sup>th</sup>, 2023

## 251 SUPPLEMENTARY REFERENCES

- 252 1. Mollenhauer B, Trautmann E, Sixel-Döring F, Wicke T, Ebentheuer J, Schaumburg M, Lang
- 253 E, Focke NK, Kumar KR, Lohmann K, Klein C, Schlossmacher MG, Kohnen R, Friede T,
- 254 Trenkwalder C; DeNoPa Study Group. (2013) Nonmotor and diagnostic findings in subjects
- with de novo Parkinson disease of the DeNoPa cohort. *Neurology* 81(14): 1226-34
- Hughes, A. J., Daniel, S. E., Kilford, L. & Lees, A. J. Accuracy of clinical diagnosis of
   idiopathic Parkinson's disease. A clinico-pathological study of 100 cases. *J. Neurol. Neurosurg. Psychiatry* 55, 181–184 (1992).
- 259 3. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan
- I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH,
  Deuschl G. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord*. 2015
  Oct;30(12):1591-601.
- 4. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. (1997) 'Sniffin' sticks': olfactory
  performance assessed by the combined testing of odor identification, odor discrimination and
  olfactory threshold. *Chem Senses*. 22(1):39-52.
- Concha-Marambio L, Weber S, Farris CM, Dakna M, Lang E, Wicke T, Ma Y, Starke M,
   Ebentheuer J, Sixel-Döring F, Muntean ML, Schade S, Trenkwalder C, Soto C, Mollenhauer
- 268 B. (2023) Accurate Detection of α-Synuclein Seeds in Cerebrospinal Fluid from Isolated
- Rapid Eye Movement Sleep Behavior Disorder and Patients with Parkinson's Disease in the
  DeNovo Parkinson (DeNoPa) Cohort. *Mov Disord*. 2023 Apr;38(4):567-578.
- Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer
   W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ,
   El-Agnaf OM, Schlossmacher MG. (2008) Direct quantification of CSF alpha-synuclein by
   ELISA and first cross-sectional study in patients with neurodegeneration. *Exp Neurol.*
- 275 213(2):315-25.
- Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C,
   Schlossmacher MG. (2011) α-Synuclein and tau concentrations in cerebrospinal fluid of
   patients presenting with parkinsonism: a cohort study. *Lancet Neurol*. 2011 Mar;10(3):230 40. doi: 10.1016/S1474-4422(11)70014-X. Erratum in: *Lancet Neurol*. 2011 Apr;10(4):297.

It is made available under a CC-BY 4.0 International license .

Supplementary Appendix

December 18<sup>th</sup>, 2023

280 8. Mollenhauer B, Trautmann E, Taylor P, Manninger P, Sixel-Döring F, Ebentheuer J,

- Trenkwalder C, Schlossmacher MG. (2013) Total CSF α-synuclein is lower in de novo
  Parkinson patients than in healthy subjects. *Neurosci Lett.* 532:44-8.
- 9. Ho J.W., Tumkaya T., (2020). *dabestr: Data Analysis using Bootstrap-Coupled Estimation*.
  https://cran.r-project.org/web/packages/dabestr/index.html
- Wickham H (2016). ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York.
  ISBN 978-3-319-24277-4, https://ggplot2.tidyverse.org.
- 11. Robin X., et al. (2023). pROC: Display and Analyze ROC Curves. https://cran.r project.org/web/packages/pROC/index.html

It is made available under a CC-BY 4.0 International license .

Supplementary Appendix

December 18<sup>th</sup>, 2023

# 290 ACKNOWLEDGEMENTS


- 291 This research was funded in part by Aligning Science Across Parkinson's [Grant ID: ASAP-
- 292 020625] administered by the Michael J. Fox Foundation for Parkinson's Research (MJFF) and by
- 293 the Parkinson Research Consortium Ottawa.

It is made available under a CC-BY 4.0 International license .

Figures


December 18th, 2023

295 A











- 299
- 300
- 301
- 302





Figure 1: Association of chronically reduced olfaction with α-synuclein-linked brain diseases 306

It is made available under a CC-BY 4.0 International license .

#### Figures

December 18th, 2023

## 308



# 309

310

311

	Coefficient	p-value
(Intercept)	0.02151	0.287
Month	-9.23E-05	0.188
Group: PD	-0.004101	0.466
Group: RBD_Not converted	-0.008664	0.351
Group: RBD_Converted	-0.01197	0.276
Age	-0.000252	0.4
Sex: Male	-0.001891	0.708


# 312 <u>Suppl. Figure S1:</u> Rate of changes of SST-ID scores over time.

It is made available under a CC-BY 4.0 International license .

#### Figures


December 18th, 2023

# A: Total α-synuclein in CSF by group and sex




	Coefficient	p-value	
(Intercept)	785.093	0.048464	*
Group: PD	-88.454	0.50093	
Group: OND	-53.941	0.755369	
Age	16.607	0.00432	**
Sex: Male	-370.055	0.000371	***
Olfaction: Reduced	-28.366	0.822528	

B: Total tau in CSF by group and sex



	Coefficient	p-value	
(Intercept)	39.256	0.599	
Group: PD	-30.589	0.22	
Group: OND	12.407	0.699	
Age	4.324	0.0000982	***
Sex: Male	-79.644	0.0000584	***
Olfaction: Reduced	8.801	0.712	

## C: Phosphorylated tau in CSF by group and sex




	Coefficient	p-value	
(Intercept)	21.6646	0.039964	*
Group: PD	-3.9124	0.258921	
Group: OND	-1.2608	0.789619	
Age	0.4845	0.001663	**
Sex: Male	-9.8005	0.000468	***
Olfaction: Reduced	1.0947	0.742111	

It is made available under a CC-BY 4.0 International license .

Figures


December 18th, 2023

# D: Ab42 in CSF by group and sex




Estimate	Pr(> t )	
894.6618	1.82E-10	***
-66.8745	0.1294	
-94.3713	0.0976	
-0.1737	0.9279	
-5.0841	0.8818	
69.7542	0.0994	
	894.6618 -66.8745 -94.3713 -0.1737 -5.0841	894.6618         1.82E-10           -66.8745         0.1294           -94.3713         0.0976           -0.1737         0.9279           -5.0841         0.8818

#### E: Total protein content of CSF by group and sex



	Coefficient	p-value	
(Intercept)	589.587	0.00277	**
Group: PD	121.162	0.06337	
Group: OND	166.213	0.0487	*
Age	-2.386	0.39993	
Sex: Male	93.304	0.06529	
Olfaction: Reduced	-48.689	0.43644	

# F: Normalized total α-synuclein in CSF by group and sex




	Coefficient	p-value	
(Intercept)	2.35543	0.041	*
Group: PD	-0.70624	0.0646	
Group: OND	-0.61559	0.2204	
Age	0.03662	0.0289	*
Sex: Male	-1.44577	2.20E-06	***
Olfaction: Reduced	0.0792	0.8288	

It is made available under a CC-BY 4.0 International license .

Figures


*December* 18<sup>th</sup>, 2023

## **G:** Normalized total tau in CSF by group and sex




	Coefficient	p-value	
(Intercept)	0.203781	0.32572	
Group: PD	-0.145039	0.03651	*
Group: OND	-0.055866	0.53023	
Age	0.009416	0.00202	**
Sex: Male	-0.284432	3.33E-07	***
Olfaction: Reduced	0.034067	0.60652	

#### H: Normalized phosphorylated tau in CSF by group and sex



	Coefficient	p-value	
(Intercept)	0.0713408	0.0289	*
Group: PD	-0.021574	0.0451	*
Group: OND	-0.0179481	0.2205	
Age	0.0010134	0.032	*
Sex: Male	-0.0413419	2.64E-06	***
Olfaction: Reduced	0.0052111	0.6126	

#### I: Normalized Ab42 in CSF by group and sex



	Estimate	Pr(> t )	
(Intercept)	2.180539	1.4E-05	***
group: PD	-0.418569	0.01084	*
group: OND	-0.524225	0.01338	*
age	0.001771	0.80309	
sex: Male	-0.396461	0.00202	**
olfaction: Reduced	0.206328	0.18744	

314 <u>Suppl. Figure S2:</u> Relationship between select CSF biomarkers and disease group and sex.